Document:

exv10w18

Exhibit 10.18

AMENDMENT NO. 1

TO

CONSULTING AGREEMENT

     This Amendment No. 1 to the Consulting Agreement dated July 1, 2008 (“Agreement”), is
hereby entered into and effective as of March 16, 2010 (“Amendment No. 1 Effective Date”),
by and between Spectrum Pharmaceuticals, Inc., a Delaware corporation, with an office located at
157 Technology Drive, Irvine, California 92618 (“Spectrum”), and Luigi Lenaz, M.D., located
at 11 Planetree Court, PA 18940 (“Consultant”). Capitalized terms not defined herein shall
have the meaning set forth in the Agreement.

     The parties agree that an amendment needs to be made to the Agreement.

     The parties agree to enter into this Amendment No. 1 to amend the Agreement, as set forth
below:

	 	1.	 	Section 1, shall be replaced, in its entirety, as follows:
	 
	 	 	 	Consulting Services. The Consultant agrees to perform consulting and advisory
services as may be requested by Spectrum, related to Spectrum’s products, and as
Spectrum and the Consultant shall agree from time to time. The Consultant shall
render such services either in person (at Spectrum or at such other location as is
reasonably acceptable to Spectrum and the Consultant) or by telephone, as Spectrum
may reasonably request.
	 
	 	2.	 	Section 2, shall be modified, as follows:

	 	•	 	Spectrum will pay Consultant a retainer of $33,333 per month from this
Amendment No. 1 Effective Date through June 18, 2010.
	 
	 	•	 	For services rendered on or after June 18, 2010, Consultant will revert to a
payment rate of $400 per hour.
	 
	 	•	 	Spectrum will also reimburse Consultant for all travel (Business Class for
flights 3 or more hours in duration) and other out of pocket expenses
reasonably incurred by Consultant in connection with his consultation services,
so long as, in the case of a travel assignment, the assignment is undertaken at
the Spectrum’s request or otherwise preapproved by Spectrum in advance.
Consultant’s travel time during any travel assignment hereunder, including
visits to Spectrum’s office, will be deemed to be time incurred in the
performance of services hereunder. Appropriate documentation should be
forwarded to Spectrum showing expenses, substantially in accordance with
Spectrum documentation requirements applicable to its employees in the ordinary
course.

     All other provisions of the Agreement remain in full force and effect.

Agreed and Accepted as of the Amendment No. 1 Effective Date.

	 	 	 	 	 	 	 

	Spectrum Pharmaceuticals, Inc.	 	Luigi Lenaz, M.D.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Shyam Kumaria
	 	By:
	 	/s/ Luigi Lenaz, M.D.
	 

	 	 
	 	 	 	 
	 

	 	Shyam Kumaria
	 	 	 	Signature
	 

	 	V.P., Financeexv10w19

Exhibit 10.19

AMENDMENT NO. 2

TO

CONSULTING AGREEMENT

     This Amendment No. 2 to the Consulting Agreement dated July 1, 2008 (“Agreement”), is
hereby entered into and effective as of July 2 2010 (“Amendment No. 2 Effective Date”), by
and between Spectrum Pharmaceuticals, Inc., a Delaware corporation, with an office located at 157
Technology Drive, Irvine, California 92618 (“Spectrum”), and Luigi Lenaz, M.D., located at
11 Planetree Court, Newtown, PA 18940 (“Consultant”). Capitalized terms not defined herein
shall have the meaning set forth in the Agreement.

     The parties agree that an amendment needs to be made to the Agreement.

     The parties agree to enter into this Amendment No. 2 to amend the Agreement, as set forth
below:

	 	1.	 	Section 1, shall be replaced, in its entirety, as follows:
	 
	 	 	 	Consulting Services. The Consultant agrees to perform consulting and advisory
services as may be requested by Spectrum, related to Spectrum’s products, and as
Spectrum and the Consultant shall agree from time to time. The Consultant shall
render such services either in person (at Spectrum or at such other location as is
reasonably acceptable to Spectrum and the Consultant) or by telephone, as Spectrum
may reasonably request.
	 
	 	2.	 	Section 2, shall be modified, as follows:

	 	•	 	For consulting services rendered on or after July 2, 2010, Consultant will
revert to a payment rate of $250 per hour.
	 
	 	•	 	Spectrum will also reimburse Consultant for all travel (Business Class for
flights 3 or more hours in duration) and other out of pocket expenses
reasonably incurred by Consultant in connection with his consultation services,
so long as, in the case of a travel assignment, the assignment is undertaken at
the Spectrum’s request or otherwise preapproved by Spectrum in advance.
Consultant’s travel time during any travel assignment hereunder, including
visits to Spectrum’s office, will be deemed to be time incurred in the
performance of services hereunder. Appropriate documentation should be
forwarded to Spectrum showing expenses, substantially in accordance with
Spectrum documentation requirements applicable to its employees in the ordinary
course.

     All other provisions of the Agreement remain in full force and effect.

Agreed and Accepted as of the Amendment No. 2 Effective Date.

	 	 	 	 	 	 	 

	Spectrum Pharmaceuticals, Inc.	 	Luigi Lenaz, M.D.
	 
	 	 	 	 	 	 
	By:

	 	/s/ Shyam Kumaria
	 	By:
	 	/s/ Luigi Lenaz, M.D.
	 

	 	 
	 	 	 	 
	 

	 	Shyam Kumaria

S.V.P., Finance
	 	 	 	Signatureexv10w34

Exhibit 10.34

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT MARKED WITH [***] 
HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE 
COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

CONFIDENTIAL

FIRST AMENDMENT TO SUPPLY AGREEMENT

     THIS FIRST AMENDMENT TO SUPPLY AGREEMENT (this “Amendment”), dated as of December 15, 2008
(the “Amendment Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation
(“CTI”), and BIOGEN IDEC INC., a Delaware corporation (“Manufacturer”).

     WHEREAS, CTI and Manufacturer are parties to that certain Supply Agreement dated as of
December 21, 2007 (the “Supply Agreement”), and capitalized terms not defined in this Amendment
shall have the meanings ascribed to them in the Supply Agreement;

     WHEREAS, pursuant to the Supply Agreement, CTI has engaged Manufacturer to (i) manufacture and
supply Finished US Goods and (ii) undertake certain efforts toward the goal of eventually
transferring the manufacture of Bulk Product and the supply of Finished US Goods for Buyer’s
requirements from Manufacturer and its subcontractors to Buyer or to Buyer’s designee(s) so that
Buyer and/or Buyer’s designee(s) could commence the manufacture of Bulk Product and the supply of
Finished US Goods no later than the end of the Term (or, if applicable, thirty-six (36) months
after a Mid-Term Transfer Election);

     WHEREAS, CTI proposes to enter into a joint venture with Spectrum Pharmaceuticals, Inc., a
Delaware corporation (“Spectrum”), for the marketing and development of the Product (the “Joint
Venture Transaction”), which will entail the contribution by CTI to RIT Oncology, LLC, a
newly-formed Delaware limited liability company (“RIT”), of all of CTI’s right, title and interest
in the Supply Agreement (as amended hereby) and related documents, although CTI will remain liable
for the performance of each of the assigned obligations; and

     WHEREAS, CTI and Manufacturer desire to amend the Supply Agreement in advance of CTI
consummating the Joint Venture Transaction.

     NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
CTI and Manufacturer agree as follows:

     1. Third Party Consents. In connection with the Joint Venture Transaction, and
notwithstanding any provision of the Supply Agreement to the contrary, CTI acknowledges and agrees
that Manufacturer shall have no obligation whatsoever to manufacture the Bulk Product or to supply
any Finished US Goods (for CTI, RIT or any other party), whether pursuant to the Supply Agreement
or otherwise, unless and until CTI has obtained written consents to the Joint Venture Transaction
(including, without limitation, the licensing or sublicensing to RIT of intellectual property
rights with respect to the Product) from the other parties to the following license and sublicense
agreements (with copies of such written consents to be provided to Manufacturer) such

 

 

that RIT thereupon and thereafter maintains rights under such agreements that are
substantially similar to CTI’s rights (relative to the Product) as existed immediately prior to the
Amendment Date:

          (a) Sublicense Agreement, [***];

          (b) Sublicense Agreement, [***];

          (c) Sublicense Agreement, [***];

          (d) Nonexclusive Agreement, [***]; and

          (e) License Agreement, [***].

     In connection with the Joint Venture Transaction, and notwithstanding any provision of the
Supply Agreement to the contrary, CTI further acknowledges and agrees that Manufacturer shall have
no obligation whatsoever to manufacture the Bulk Product or to supply any Finished US Goods (for
CTI, RIT or any other party), whether pursuant to the Supply Agreement or otherwise, unless and
until (i) CTI has assigned to RIT that certain License Agreement, dated November 28, 2007, by and
between CTI and [***] such that RIT thereupon and thereafter maintains rights under such agreement
that are no less than CTI’s rights (relative to the Product) as existed prior to any activities
associated with the Joint Venture Transaction and (ii) CTI and Manufacturer mutually terminate that
certain Sublicense Agreement, dated December 21, 2007, by and between CTI and Manufacturer (with
reference to the [***]) and concurrently therewith RIT and Manufacturer enter into a Sublicense
Agreement in the same form and substance thereof.

     Notwithstanding the foregoing, so long as Manufacturer has not received any oral or written
notice from any third party of breach or alleged breach of any of the above-referenced license and
sublicense agreements as a result of or otherwise relating to the Joint Venture Transaction or any
of the transactions in connection therewith, Manufacturer shall continue to have the obligation to
deliver and supply, and shall deliver and supply, to CTI any Finished US Goods subject to the
accepted purchase orders that remain outstanding as of the Amendment Date (i.e., purchase orders
33791 and 33897) (the “Confirmed POs”) in accordance with the terms and conditions of the Supply
Agreement. For the avoidance of doubt, consistent with Section 4, the price for any
Finished US Goods subject to the Confirmed POs shall be the Manufacturing Cost Plus [***];
provided, however, so long as CTI makes payment to BIIB with respect to purchase
order 33791 within [***] days of the Amendment Date, such price shall be [***] (which represents
Manufacturing Cost Plus [***]).

     2. Technology Transfer.

     Section 7.8(b) is hereby amended with the addition, to the end of the existing
provisions, of the following sentence:

“Without any assurances of any kind whatsoever by Manufacturer and without relieving Buyer’s
obligations to Manufacturer in any manner, in the event that Buyer is able to negotiate any
reimbursement for Buyer from any third party (such as another purchaser of

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

2

 

Bulk Product or Finished US Goods) for the costs and expenses contemplated by this
Section 7.8(b), then Buyer (as between Buyer and Manufacturer) shall be solely
entitled to such reimbursement so long as the rights and obligations of Manufacturer are not
in any way adversely affected thereby.”

     Section 7.8(e) of the Supply Agreement is hereby superseded and replaced, in its
entirety, with the following:

     “(e) Buyer hereby agrees that it shall use commercially reasonable efforts to effect a
transfer of the manufacture of Bulk Product and/or the supply of Finished US Goods, as
applicable, for Buyer’s requirements from Manufacturer and its subcontractors to Buyer
and/or to Buyer’s designees (in either instance, the “Replacement Source”) pursuant to the
applicable period of time contemplated by this Section 7.8 (or any shorter period
contemplated by the applicable manufacturing transfer project plan). Upon the grant of FDA
approval to any such Replacement Source (the “Replacement Source Approval”), Buyer shall
notify Manufacturer and not submit any further orders under this Agreement for Finished US
Goods (but not, for the avoidance of doubt and notwithstanding Section 7.8(g)(i),
Bulk Product). Irrespective of whether such Replacement Source thereafter ceases to be
authorized to manufacture and supply Bulk Product and/or Finished US Goods, as applicable,
unless Manufacturer provides written notice of termination or reduction (in Manufacturer’s
sole discretion), Buyer shall remain: (i) obligated to deliver forecasts through the end of
the Term (or such earlier date as Manufacturer may specify in its sole discretion) as
contemplated by this Agreement; (ii) committed to the amount of firm orders in respect of
any such forecasts; and (iii) otherwise obligated to purchase all of Buyer’s requirements
for Bulk Product during the Term (or such earlier date as Manufacturer may specify in its
sole discretion) exclusively from Manufacturer pursuant to this Agreement. Upon such notice
of termination, Manufacturer may (in its sole discretion) require Buyer to place a firm
order for (and accept delivery of and pay for) any amount of Bulk Product identified by
Manufacturer (it being understood that no less than that amount reasonably required by Buyer
to release [***] years’ worth of the Product into the United States market may be ordered by
Buyer in such firm order); provided, however, that to the extent such amount
is greater than that amount reasonably required by Buyer to release [***] years’ worth of
the Product into the United States market, Buyer shall not be required to pay Manufacturer
for that portion of such amount in excess of [***] years’ worth until any portion of such
excess amount of Bulk Product is used for the purposes of manufacturing Finished US Goods
(and, thereupon, Buyer shall immediately pay Manufacturer for all of such excess amount).
For the avoidance of doubt, but without limiting the foregoing, if Manufacturer requires
Buyer to place a firm order for an amount of Bulk Product reasonably required by Buyer to
release [***] years’ worth of the Product into the United States market, Buyer shall pay
Manufacturer for that portion of such amount applicable to the fourth and fifth years once
any of the Bulk Product corresponding to such years is used for the purposes of
manufacturing Finished US Goods (while Buyer shall pay for all other Bulk Product in
accordance with the terms and conditions otherwise contemplated by this Agreement).”

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

3

 

     Section 7.8 of the Supply Agreement is hereby amended to add the following
subsections (g) and (h):

     “(g) Notwithstanding any provision of this Agreement to the contrary:

     (i) At any time after December 15, 2008, Manufacturer may provide notice to
Buyer requesting Buyer to identify or proposing to Buyer a third party manufacturer
acceptable to Manufacturer (in its sole discretion) as a successor to Manufacturer
supplying Buyer with its requirements for Finished US Goods after manufacturing of
Bulk Product by Manufacturer (as applicable, the “Successor Fill/Finish
Manufacturer”). In such an event: (x) Manufacturer shall have no obligation under
this Agreement to supply Finished US Goods after the date that is [***] months (or
[***] months in the event that [***] or any of its Affiliates is the Successor
Fill/Finish Manufacturer) following the date of Manufacturer’s notice to Buyer as
contemplated by this Section 7.8(g)(i) (it being understood that
Manufacturer will only manufacture and supply Bulk Product, and this Agreement shall
be interpreted accordingly (e.g., all references to “Finished US Goods”
shall be deemed to be references to “Bulk Product,” with appropriate modification to
the provisions of this Agreement as applicable), after such date); (y) Manufacturer
shall promptly provide one (1) copy of the Manufacturing Documentation for the
purposes of supplying Finished US Goods to Buyer; and (z) Buyer shall immediately
commence discussions with the Successor Fill/Finish Manufacturer in order to enable
Buyer to prepare and submit to Manufacturer a project plan (consistent with the
processes and goals of Section 7.8(a), albeit reflecting the shorter
[***]-month or [***]-month transition period, as applicable) regarding the transfer
from Manufacturer to the Successor Fill/Finish Manufacturer of the supply of
Finished US Goods for Buyer’s requirements. The Successor Fill/Finish Manufacturer
shall, for purposes of this Agreement, be deemed a third party manufacturer
designated by Buyer, and the provisions of this Section 7.8 shall thereafter
apply to the activities of the parties (i.e., with respect to a project plan that
has the goal of enabling Buyer to effect a transfer of the supply of Finished US
Goods for Buyer’s requirements from Manufacturer and its subcontractors to the
Successor Fill/Finish Manufacturer so that the Successor Fill/Finish Manufacturer
could commence the supply of Finished US Goods no later than [***] months or [***]
months, as applicable, following the date of Manufacturer’s notice to Buyer pursuant
to the provisions of this Section 7.8(g)(i)). For the avoidance of doubt,
after such manufacturing transfer, the Successor Fill/Finish Manufacturer would be
responsible for the supply of Kits (which are comprised of a conjugate antibody
vial, an empty reaction vial, sodium acetate and a buffer) and related activities,
while Manufacturer would solely be responsible for the manufacture of Bulk Product
(i.e., the Product in refrigerated liquid bulk form or such other form as the
parties may agree, but not in final dosage and not Finished US Goods) on the terms
and conditions otherwise contemplated by this Agreement.

     (ii) The transfer of the supply of Finished US Goods for Buyer’s requirements
from Manufacturer and its subcontractors (including as contemplated pursuant to this
Section 7.8) shall be limited, at all times and in all events, to a third

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

4

 

party manufacturer, whether proposed by Manufacturer or Buyer pursuant to
Section 7.8(g)(i), that is acceptable to Manufacturer in its sole
discretion. Manufacturer may withhold its approval of any proposed third party
manufacturer for good reason or for no reason at all; provided,
however, that [***] or any of its Affiliates is hereby deemed approved by
Manufacturer. Subject to the foregoing, Manufacturer shall exercise commercially
reasonable efforts to solicit such third party manufacturer to offer Buyer
competitive financial terms for such supply upon the transfer thereof. Buyer
acknowledges and agrees that the failure of Buyer to propose a Successor Fill/Finish
Manufacturer or the failure of Manufacturer to approve a Successor Fill/Finish
Manufacturer (whether proposed by Manufacturer or Buyer) shall not extend or
otherwise modify the [***]-month or [***]-month period contemplated by Section
7.8(g)(i) (i.e., the period after which Manufacturer will have no obligation
under this Agreement to supply Finished US Goods), as applicable.

     (iii) Manufacturer shall only be required to participate in any manufacturing
transfer activities involving Finished US Goods for [***] months or [***] months (or
any shorter period contemplated by the applicable manufacturing transfer project
plan), as applicable, and such participation shall be limited to: (w) providing
appropriate answers during normal business hours to Buyer’s specific, reasonable
questions; (x) providing appropriate assistance upon Buyer’s reasonable request to
Buyer’s preparation of regulatory submissions; (y) participating in one (1) meeting
(lasting no longer than one day during normal business hours) at the end of such
period at a location designated by Buyer for a final review of such activities; and
(z) no more than a total of ten (10) person-days of time, in the aggregate for all
participation, by all personnel. For the avoidance of doubt, such manufacturing
transfer activities include transferring stability programs and release testing
methods and assays (and, accordingly but without limitation, Manufacturer’s
obligations under Sections 5.1, 5.2 and 5.3 shall cease upon
the conclusion of such period). Notwithstanding the last sentence of Section
7.8(a), Buyer acknowledges and agrees that, after the earlier of (A) the end of
such period or (B) the completion of such final review meeting, Manufacturer shall
still have responsibility for any manufacturing transfer activities under this
Section 7.8 with respect to Bulk Product.

     (iv) Notwithstanding Sections 3.1(a) through 3.1(g) (it being
understood that such provisions shall not apply to forecasts and orders of Bulk
Product), Buyer shall submit a [***] month forecast of its requirements for Bulk
Product no later than [***] months after Manufacturer’s notice to Buyer for a
Successor Fill/Finish Manufacturer pursuant to Section 7.8(g)(i) and provide
an updated forecast every [***] months thereafter. The forecasted requirement for a
period that is [***] months or less into the forecasted period shall be a firm order
(and an order form shall accompany such order), except that Buyer shall not place
orders more frequently than twice per year (i.e., every other forecast shall be
deemed a firm order, as noted with Buyer’s accompanying order form).

     (h) Notwithstanding any provision of this Agreement to the contrary:

     (i) At any time after December 15, 2008, Manufacturer may provide

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

5

 

notice to Buyer requesting Buyer to identify or proposing to Buyer a third
party manufacturer acceptable to Manufacturer (in its sole discretion) as a
successor to Manufacturer for manufacturing Bulk Product and, as applicable,
supplying Buyer with its requirements for Finished US Goods (as applicable, the
“Successor Manufacturer”). In such an event: (x) the end of the Term may be
accelerated in Manufacturer’s sole discretion to a date that is at or [***] months
following the date of Manufacturer’s notice to Buyer as contemplated by this
Section 7.8(h)(i); (y) Manufacturer shall promptly provide one (1) copy of
the Manufacturing Documentation to Buyer; and (z) Buyer shall immediately commence
discussions with the Successor Manufacturer in order to enable Buyer to prepare and
submit to Manufacturer a project plan (as contemplated by Section 7.8(a))
regarding the transfer from Manufacturer to the Successor Manufacturer of the
manufacture of Bulk Product and, as applicable, the supply of Finished US Goods for
Buyer’s requirements. The Successor Manufacturer shall, for purposes of this
Agreement, be deemed a third party manufacturer designated by Buyer, and the
provisions of this Section 7.8 shall thereafter apply to the activities of
the parties (i.e., with respect to a project plan that has the goal of enabling
Buyer to effect a transfer of the manufacture of Bulk Product and, as applicable,
the supply of Finished US Goods for Buyer’s requirements from Manufacturer and its
subcontractors to the Successor Manufacturer so that the Successor Manufacturer
could commence the manufacture of Bulk Product and, as applicable, the supply of
Finished US Goods no later than the end of a [***]-month period following
Manufacturer’s notice as contemplated by this Section 7.8(h)(i)).

     (ii) The transfer of the manufacture of Bulk Product and/or the supply of
Finished US Goods for Buyer’s requirements from Manufacturer and its subcontractors
(including as contemplated pursuant to this Section 7.8) shall be limited,
at all times and in all events, to a third party manufacturer, whether proposed by
Manufacturer (i.e., pursuant to Section 7.8(h)(i)) or by Buyer, that is
acceptable to Manufacturer in its sole discretion. Manufacturer may withhold its
approval of any proposed third party manufacturer for good reason or for no reason
at all. Subject to the foregoing, Manufacturer shall exercise commercially
reasonable efforts to consult with Buyer with respect to the identity and
qualifications of such third party manufacturer and to solicit such third party
manufacturer to offer Buyer competitive financial terms for such manufacture upon
the transfer thereof Buyer acknowledges and agrees that the failure of Buyer to
propose a Successor Manufacturer or the failure of Manufacturer to approve a
Successor Manufacturer (whether proposed by Manufacturer or Buyer) shall not extend
or otherwise modify the [***]-month or longer period contemplated by Section
7.8(h)(i) (i.e., the period after which Manufacturer will have no obligation
under this Agreement to manufacture of Bulk Product and/or supply Finished US
Goods).

     (iii) Notwithstanding any provision of this Agreement to the contrary,
Manufacturer shall only be required to participate in any manufacturing transfer
activities involving Bulk Product for [***] months (or any shorter period
contemplated by the applicable manufacturing transfer project plan) and such
participation shall be limited to: (w) providing appropriate answers during normal

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

6

 

business hours to Buyer’s specific, reasonable questions; (x) providing
appropriate assistance upon Buyer’s reasonable request to Buyer’s preparation of
regulatory submissions; (y) participating in one (1) meeting (lasting no longer than
one day during normal business hours) at the end of such period at a location
designated by Buyer for a final review of such activities; and (z) no more than a
total of [***] person-days of time, in the aggregate for all participation, by all
personnel. For the avoidance of doubt, such manufacturing transfer activities
include transferring stability programs and release testing methods and assays (and,
accordingly but without limitation, Manufacturer’s obligations under Sections
5.1, 5.2 and 5.3 shall cease upon the conclusion of such
period), but only to the extent such transfer did not previously occur in connection
with manufacturing transfer activities for Finished US Goods pursuant to Section
7.8(g). Without limiting the last sentence of Section 7.8(a), Buyer
acknowledges and agrees that, after the earlier of (A) the end of such period or (B)
the completion of such final review meeting, Manufacturer shall have no
responsibility for any manufacturing transfer activities under this Section
7.8 or otherwise.”

     3. Term. Section 8.1 of the Supply Agreement is hereby superseded and
replaced, in its entirety, with the following:

     “8.1 Term. This Agreement shall commence on the Effective Date and shall
expire on June 9, 2014, unless earlier terminated in accordance with this Article
VIII (the “Term”); provided, however, that if Manufacturer identifies and proposes to
Buyer a Successor Manufacturer as contemplated by Section 7.8(h)(i), then the end of
the Term may be accelerated in Manufacturer’s sole discretion to a date that is at or beyond
[***] months following the date of Manufacturer’s notice to Buyer as contemplated by
Section 7.8(h)(i).”

     4. Manufacturing Cost.

          (a) The definition of “Manufacturing Cost” contained in Section 1.1 of the Supply
Agreement shall be revised to delete the entire last sentence of the definition as set forth in the
Supply Agreement.

          (b) The definition of “Manufacturing Cost Plus [***]” contained in Section 1.1 of the
Supply Agreement shall, for all purposes from and after the Amendment Date, be revised and replaced
in its entirety with the following:

     “Manufacturing Cost Plus [***]” means, with respect to any Finished US Goods at issue,
the Manufacturing Cost for such Finished US Goods multiplied by [***] and, after completion
of the manufacturing transfer activities for Finished US Goods pursuant to Section
7.8(g) (i.e., when Manufacturer is only responsible under this Agreement to manufacture
and supply Bulk Product), as applicable, and with respect to any Bulk Product at issue, the
Manufacturing Cost for such Bulk Product multiplied by [***].”

          (c) All references to “Manufacturing Cost Plus [***]” contained throughout the

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

7

 

Supply Agreement shall, for all purposes from and after the Amendment Date, be replaced with
“Manufacturing Cost Plus [***].”

     5. Disputed Invoice. [***] Manufacturer and CTI hereby resolve in its entirety such
dispute and agree that CTI shall make no payment to Manufacturer in respect of the Invoice.

     6. No Other Changes. Except as amended hereby, the Supply Agreement remains in full
force and effect.

     7. Miscellaneous. This Amendment will be deemed to have been made in the State of
California and its form, execution, validity, construction and effect will be determined in
accordance with the laws of the State of California, without giving effect to the principles of
conflicts of law thereof. This Amendment shall be binding upon and inure to the benefit of the
parties and their respective successors and assigns. This Amendment may be executed in separate
counterparts, each of which shall be deemed an original and all of which together shall constitute
one and the same instrument. Signatures on counterparts of this Amendment transmitted by facsimile
or e-mail shall be deemed effective for all purposes.

[SIGNATURE PAGE FOLLOWS]

[***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

8

 

     IN WITNESS WHEREOF, the parties have caused this Amendment to be signed by their
respective representatives thereunto duly authorized as of the Amendment Date.

	 	 	 	 	 
	 	

BIOGEN IDEC INC.

 	 
	 	By:  	/s/ Paul J. Clancy
 	 
	 	 	Name:  	Paul J. Clancy 	 
	 	 	Title:  	Chief Financial Officer 	 
	 
	 	CELL THERAPEUTICS, INC.

 	 
	 	By:  	/s/ Louis A. Bianco
 	 
	 	 	Name:  	Louis A. Bianco 	 
	 	 	Title:  	Exec. Vice President, Finance and
Admin. 	 
	 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]